<SEC-DOCUMENT>0001564590-19-010621.txt : 20190403
<SEC-HEADER>0001564590-19-010621.hdr.sgml : 20190403
<ACCEPTANCE-DATETIME>20190402190019
ACCESSION NUMBER:		0001564590-19-010621
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190402
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190403
DATE AS OF CHANGE:		20190402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IRIDEX CORP
		CENTRAL INDEX KEY:			0001006045
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				770210467
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1229

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-27598
		FILM NUMBER:		19726892

	BUSINESS ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
		BUSINESS PHONE:		6509404700

	MAIL ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>irix-8k_20190402.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
irix-8k_20190402.DOCX.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:130.5pt;"></td>
<td style="width:0.9pt;"></td>
<td style="width:24.6pt;"></td>
<td style="width:156pt;"></td>
<td style="width:30pt;"></td>
<td style="width:0.9pt;"></td>
<td style="width:125.1pt;"></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;;font-size:16pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:36pt;;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:3pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:16pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8&#8209;K</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:12pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr>
<td colspan="7" valign="middle" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:11pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO SECTION 13 OR 15(d) OF THE<br />SECURITIES EXCHANGE ACT OF 1934</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p></td>
<td colspan="4" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">April 2, 2019</p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Date of Report (date of earliest event reported)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:22pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IRIDEX CORPORATION</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">0-27598</p></td>
<td colspan="3" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">77-0210467</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of<br />incorporation or organization)</p></td>
<td valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td colspan="3" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification Number)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1212 Terra Bella Avenue<br />Mountain View, California 94043</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;letter-spacing:0pt;font-weight:bold;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices, including zip code)</p></td>
</tr>
<tr style="height:20.25pt;">
<td colspan="2" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p></td>
<td colspan="4" valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:10pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(650) 940-4700</p></td>
<td valign="top" >
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p></td>
</tr>
<tr style="height:11.65pt;">
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="4" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:8pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;">&nbsp;</p></td>
</tr>
<tr style="height:20.25pt;">
<td colspan="7" valign="top" >
<p style="margin-top:12pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-weight:bold;">&nbsp;</p></td>
</tr>
<tr style="height:11.65pt;">
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-size:8pt;letter-spacing:0pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report)</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:normal;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:22.3pt;;margin-right:0.21%;text-indent:-22.3pt;;font-size:10.5pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Check1"></a><font style="font-size:10.5pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Check1"></a>&#9744;</font><font style="font-size:11pt;"></font><font style="font-weight:bold;font-size:11pt;"></font><font style="font-size:11pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:22.3pt;;margin-right:0.21%;text-indent:-22.3pt;;font-size:10.5pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10.5pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font><font style="font-size:11pt;"></font><font style="font-weight:bold;font-size:11pt;"></font><font style="font-size:11pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:22.3pt;;margin-right:0.21%;text-indent:-22.3pt;;font-size:10.5pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Check3"></a><font style="font-size:10.5pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Check3"></a>&#9744;</font><font style="font-size:11pt;"></font><font style="font-weight:bold;font-size:11pt;"></font><font style="font-size:11pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:22.3pt;;margin-right:0.21%;text-indent:-22.3pt;;font-size:10.5pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10.5pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font><font style="font-size:11pt;"></font><font style="font-size:11pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.21%;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.21%;text-indent:0pt;;font-size:10pt;letter-spacing:-0.2pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.21%;text-indent:0pt;;font-size:10pt;letter-spacing:0pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&nbsp;&nbsp;<font style="font-size:11pt;font-family:'Times New Roman';">&#9744;</font><font style="font-size:11pt;"></font></p></td>
</tr>
<tr>
<td colspan="7" valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.21%;text-indent:0pt;;font-size:10pt;letter-spacing:0pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;<font style="font-size:11pt;font-family:'Times New Roman';">&#9744;</font><font style="font-size:11pt;"></font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.64%;width:112.8%;"></table></div>
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.64%;width:112.8%;">
<tr>
<td style="width:10.95%;"></td>
<td style="width:101.85%;"></td>
</tr>
<tr>
<td style="width:10.95%;"></td>
<td style="width:101.85%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item </font><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.0</font><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:15pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(d)&nbsp;&nbsp;Appointment of Directors </p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:3.42%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 2, 2019, the Company appointed Kenneth E. Ludlum to the board of directors (the &#8220;Board&#8221;) of Iridex Corporation (the &#8220;Company&#8221;), effective April 2, 2019 (the &#8220;Effective Date&#8221;).&nbsp;&nbsp;In connection with Mr. Ludlum&#8217;s appointment to the Board: 1) the size of the Board was increased from six to seven members as of the Effective Date and 2) Sanford Fitch has decided that that he will not stand for re-election at the Company&#8217;s 2019 annual meeting of stockholders, but will continue to serve as a member of the Board until the expiration of his current term ending on the date of the 2019 annual meeting.&nbsp;&nbsp;As a result, Mr. Fitch&#8217;s resignation will be effective immediately prior to the 2019 annual meeting of stockholders.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.42%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Ludlum will receive standard compensation available to non-employee members of the Board and committees of the Board and each will receive an option to purchase 15,000 shares of the Company&#8217;s common stock which vests in <font style="color:#000000;">in equal monthly installments over four years following the effective date of the grant.&nbsp;&nbsp;In addition, it is expected that Mr. Ludlum will execute the Company&#8217;s standard form of indemnification agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.42%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Ludlum is a professional board member with medical technology and biotechnology companies.&nbsp;&nbsp; <font style="color:#000000;">Since 2002, Mr. Ludlum has served on the board of directors and as Chairman of the Audit Committee at NATUS Medical Incorporated and as Chairman of its Compensation Committee since June 2018.&nbsp;&nbsp;NATUS Medical Incorporated is a medical device and equipment company.&nbsp;&nbsp;From February 2014 to April 2016, Mr. Ludlum served as Chief Financial Officer at CareDx, a molecular diagnostics company, and prior to that has served as Chief Financial Officer for other publicly traded companies.&nbsp;&nbsp;Mr. Ludlum has worked for or with health care, medical device, biotechnology or diagnostic companies since 1985.&nbsp;&nbsp;</font>Mr. Ludlum holds a B.S. in Business Administration from Lehigh University and a M.B.A. from Columbia University Graduate School of Business.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.42%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no arrangements or understandings between Mr. Ludlum and any other person pursuant to which Mr. Ludlum was elected as directors of the Company.&nbsp;&nbsp;There are no family relationships between Mr. Ludlum and any director or executive officer of the Company, and, other than as described above, no transactions involving Mr. Ludlum that would require disclosure under Item 404(a) of Regulation S-K.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.57%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s press release dated April 2, 2019 regarding Mr. Ludlum&#8217;s appointments is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:103.54%;">
<tr>
<td style="width:12.5%;"></td>
<td style="width:91.04%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01.</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financial Statements and Exhibits. </p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:100%;">
<tr>
<td style="width:3.7%;"></td>
<td style="width:96.3%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibits </p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.71%;"></td>
<td style="width:6.7%;"></td>
<td style="width:85.6%;"></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1*</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1006045/000156459016021155/irix-8k_20160708.htm"><font style="text-decoration:underline;">Form of Indemnification Agreement between the Company and its directors and officers.</font> </a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="irix-ex991_7.htm"><font style="text-decoration:underline;">Press Release dated April 2, 2019.</font></a></p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* Incorporated by reference to the Exhibits filed with the Registrant&#8217;s Report on Form 8-K on July 11, 2016.<font style="font-size:11pt;">.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">-2</a>-</p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:41.65%;">
<tr>
<td style="width:4.06%;"></td>
<td style="width:1.74%;"></td>
<td style="width:35.85%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IRIDEX CORPORATION</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ William M. Moore</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">William M. Moore</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: April 2, 2019 </p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">-3</a>-</p></td></tr></table></div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>irix-ex991_7.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
irix-ex991_7.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtq3l2eui5a3000001.jpg" title="" alt="" style="width:96px;height:92px;"></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">For Immediate Release</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Ken Ludlum Appointed to IRIDEX Board of Directors</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Mountain View, Calif. April 2, 2019<font style="font-weight:normal;"> -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that Ken Ludlum has been appointed to its Board of Directors, effective immediately. Ludlum with also serve on the Company&#8217;s Compensation and Audit committees.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are delighted to welcome Ken to our board. His extensive background in both operational and financial roles with medical technology companies is highly complementary to our current board and strengthens the overall IRIDEX leadership team.&nbsp;&nbsp;I look forward to his insight and guidance in advancing our role in the treatment of sight-threatening eye disease,&#8221; said William M. Moore, Chairman and Chief Executive Officer.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ludlum brings a wealth of relevant experience in the medical technology sector, which includes leadership roles as board member, executive officer, investor, and advisor.&nbsp;&nbsp;He currently serves on the board and as Chairman of the Audit Committee at NATUS Medical, a publicly held medical device company and at Personalis, Inc., a venture backed molecular diagnostics company.&nbsp;&nbsp;Previously, Ludlum served on the board of directors for Novacept Corporation, Thermage Corporation, AtheroMed, Bridgeway Plan for Health and Kinetikos Medical.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ludlum also served as Chief Financial Officer of CareDx, a molecular diagnostics company, through the company's initial public offering in 2014.&nbsp;&nbsp;Prior to that, he served in executive roles at two medical device companies, including President and CEO of Revivant Corporation and CFO of Perclose Inc. Prior to 25 years in operating positions, Ludlum spent 10 years as an investment banker, primarily with Montgomery Securities.&nbsp;&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">"I am honored to have the opportunity to join IRIDEX's Board of Directors," said Ludlum. &#8220;Throughout my career I&#8217;ve sought opportunities for innovation in medical technology and believe that IRIDEX is bringing exciting new technology to the treatment of glaucoma and retinal disease that clearly benefits both providers and patients. I am very much looking forward to helping the company continue to advance their business and help patients with their unique laser-based approach to treatment.&#8221;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ludlum holds a Bachelor of Science degree from Lehigh University and an MBA from Columbia Business School. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#333333;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About&#160;IRIDEX</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#333333;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>IRIDEX is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company&#8217;s proprietary MicroPulse&#174; technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions.&#160;IRIDEX&#8217;s current product line is used for </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#333333;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#333333;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in&#160;the United States </font><font style="color:#333333;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Germany </font><font style="color:#333333;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">through a direct sales force and</font><font style="color:#333333;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in</font><font style="color:#333333;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> more than 100 countries through a network of independent distributors. For </font><font style="color:#333333;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more</font><font style="color:#333333;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> information, visit </font><font style="text-decoration:underline;color:#000000;">http://www.</font><font style="text-decoration:underline;color:#000000;">iridex.com</font><font style="color:#06A0CF;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations Contact:<font style="font-weight:normal;"><br />Leigh Salvo<br />(415) 937-5404<br />investors@iridex.com</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Media Contact:<font style="font-weight:normal;"><br />Jamie Hall <br />Pascale Communications, LLC.<br />(724) 417-0167<br />pr@iridex.com</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gtq3l2eui5a3000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtq3l2eui5a3000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0""17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      #<     0   -P    !  .@ 0 #     0 !  "@ @ $     0   -R@
M P $     0   -,       #_VP!#  $! 0$! 0(! 0(" @(" @," @(" P0#
M P,# P0%! 0$! 0$!04%!04%!04&!@8&!@8'!P<'!P@(" @(" @(" C_VP!#
M 0$! 0(" @," @,(!04%" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" C_P  1" #3 -P# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M22 )$$ ,CD8+DG^M;0M/L-)T>VTK2H8K:UM84MK:WA4)'%%$-B(B@ !54
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M^G#1*_H,K^?/_@L__P G2_LB?]E1F_\ 3AHE>IPY_O+_ ,%3_P!-R/(XH?\
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M^UD^6-_B>WZMOR2;ZV/[^Q>8TZ4_9).4[7Y5O;SZ)=G)I/9,_1_]N+_@LG\
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MLSPJ/#OQIT=9;R"-8]-\2:<([?6]/ E68K;7FQF$;LO[R)P\3@D,A!-?Q/\
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M7O$U]#+<)%HEK(9VM?D23=<ZF8VBAC*Y90[ -MVG_14_X(T_"#QSX^B\6?\
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MXCU*Y^W:C##< QS)91+'%##(8S\L[^<5).(E8*X_G,6-(@%B544<*B#:JCL
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MV;QSI-MKL2KM%QC[+-D*,9DA5HST)/[O.3U&,5_J,ZQ_P28\2_ _Q%=^*O\
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M76GP\\.1ZO?7>J2FVLO#/AFVEDFN2V9-@MK4-),55<_O"<!23@9-?L/\(/\
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M%B^U[PX_B.[\5^(_#-Z]QIEYIL.M:E*[BS=+B2*:*W>X@C5"(W92S ?*%/\
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MN]<]10:=$?S4^"[FVL?%NE7UZZQPP:E:2S2.?E1$E5F8^P -?ZP[_P#!=_\
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MMX4T;0/#NH1W=[<7>M6[6*,L:;L)#YWG2,< (AYR17^8/<#$AQG'OQ0:P/\
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ML5_\&JOQ \$^.+62Q\3>*M!B\?\ B&SFWB2"XUG4].^SPR([-Y<D5E%;QR(
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M6^^?]S_"@E%,'+9/K6A*[(0RGDC)SSU^N:SAU'UJ_<?P_P"[0$MC^\K]B?\
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;[L>E.E1?,/U]:9#W_P ]C4LO^L;ZTPF]#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
